MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma

Histopathology

Volumn 36, Issue 1, 2000, Pages 26-31

  Comin, ^a   Anichini, ^a   Boddi, ^a   Novelli, ^a   Dini, ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Immunohistochemistry; Mesothelioma; MIB 1; Prognosis; Survival

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR GROWTH;

ADULT; AGED; CELL COUNT; CELL DIVISION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MESOTHELIOMA; MIDDLE AGED; MITOTIC INDEX; PLEURAL NEOPLASMS; SURVIVAL RATE;

EID: 0033965421     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2000.00793.x     Document Type: Article

References (36)

1. 1. Antman KH, Li FP, Pass HI. Benign and malignant mesothelioma. In DeVita VT Jr, Hellman S, Rosenberg SA eds. Cancer: Principles and Practice of Oncology, 4th edn. Philadelphia: Lippincott, 1993: 1489-1508.
2. 2. Antman KH, Blum RH, Greenberger JS. Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am. J. Med. 1980; 68; 356-362.
3. 3. Astoul P, Picat-Joossen D, Viallat JR, Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma. A phase II study. Cancer 1998: 83; 2099-2104.
4. 4. Wanebo JH, Martini N, Melamed MR, Hilaris B, Beattie EJ Jr. Pleural mesothelioma. Cancer 1976; 38; 2481-2488.
5. 5. Buchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976; 31; 15-21.
6. 6. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura. A review of 123 patients. Cancer 1982; 49; 2431-2435.
7. 7. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann. Intern. Med. 1982; 96; 746-755.
8. 8. Martensson G, Hagmar B, Zettergren L. Diagnosis and prognosis in malignant pleural mesothelioma. A prospective study. Eur. J. Respir. Dis. 1984; 65; 169-178.
9. 9. Adams VI, Unni KK, Muhm Jr, Jett JR, Ilstrup DM, Bernatz PE. Diffuse malignant mesothelioma of pleura: diagnosis and survival in 92 cases. Cancer 1986; 58; 1540-1551.
10. 10. Waltz R, Koch HK. Malignant pleural mesothelioma. Some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985. Pathol. Res. Pract. 1990; 186; 124-134.
11. 11. De Pangher Manzini V, Brollo A, Franceschi S, De Matthaeis M, Talamini R, Bianchi C. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993; 72; 410-417.
12. 12. Fusco V, Ardizzoni A, Merlo F et al. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients. Anticancer Res. 1993; 13; 683-690.
13. 13. Huncharck M, Kelsey K, Mark EJ et al. Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. Anticancer Res. 1996; 16; 1265-1268.
14. 14. Johansson L, Lindén CJ. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest 1996; 109; 109-114.
15. 15. Kumar-Singh S, Vermeulen PB, Weyler J et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J. Pathol. 1997; 182; 211-216.
16. 16. Dazzi H, Thatcher N, Hasleton PS, Chatterjee AK, Lawson AM. DNA analysis by flow cytometry in malignant pleural mesothelioma: relationship to histology and survival. J. Pathol. 1990; 162; 51-55.
17. 17. Ramael M, Jacobs W, Weyler J et al. Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). J. Pathol. 1994; 172; 247-253.
18. 18. Beer TW, Buchanan R, Matthews AW, Stradling R, Pullinger N, Pethybridge RJ. Prognosis in malignant mesothelioma related to MIB-1 proliferation index and histological subtype. Hum. Pathol. 1998; 29; 246-251.
19. 19. Herndon IIJE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113; 723-731.
20. 20. Porter JM, Cheek JM. Pleural mesothelioma. Review of tumor histogenesis and report of 12 cases. J. Thorac. Cardiovasc. Surg. 1968; 55; 882-890.
21. 21. Oels HC, Harrison EG, Carr DT, Bernatz PE. Diffuse malignant mesothelioma of the pleura: a review of 37 cases. Chest 1971; 60; 564-570.
22. 22. Worn H. Möglichkeiten und Ergebnisse der chirurgischen Behandlung des malignen Pleuramesotheliomas. Thoraxchirurgie 1974; 22; 391-393.
23. 23. Klima M, Spjut HJ, Seybold WD. Diffuse malignant mesothelioma. Am. J. Clin. Pathol. 1976; 65; 583-600.
24. 24. Fischbein A, Suzuki Y, Selikoff IJ, Bekesi JG. Unexpected longevity of a patient with malignant pleural mesothelioma. Report of a case. Cancer 1978; 42; 1999-2004.
25. 25. McCormack PM, Nagasaki F, Hilaris BS, Martini N. Surgical treatment of pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 1982; 84; 834-842.
26. 26. Nauta RJ, Olsteen RT, Antman KH, Koster JK. Clinical staging and the tendency of malignant pleural mesothelioma to remain localized. Ann. Thorac. Surg. 1982; 34; 66-70.
27. 27. DaValle MJ, Faber LP, Kittle F, Jensik RJ. Extrapleural pneumonectomy for diffuse malignant mesothelioma. Ann. Thorac. Surg. 1986; 42; 612-618.
28. 28. Harvey JC, Fleischman EH, Kagan AR, Streeter OE. Malignant pleural mesothelioma: a survival study. J. Surg. Oncol. 1990; 45; 40-42.
29. 29. Mark EJ, Shin DH. Diffuse malignant mesothelioma of the pleura: a clinicopathological study of six patients with a prolonged symptom-free interval or extended survival after biopsy and a review of the literature of long term survival. Virchows Arch. A Pathol. Anat. 1993; 422; 445-451.
30. 30. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990; 17; 489-503.
31. 31. Dini S, Comin CE, Santucci M, Caldarella A. Pleural malignant mesothelioma (MM): a comparative clinicopathological study of short- and long-term survival patients. (Abstract) Path. Res. Pract. 1995; 191; 653-654.
32. 32. Weiss SW. Histological Typing of Soft Tissue Tumours, 2nd edn. Geneva: World Health Organisation, Springer, 1994: 36-37.
33. 33. Rusch VW, Ginsberg RJ. New concepts in the staging of mesothelioma. In Deslauriers J. Lacquet LK et al. eds. Thoracic Surgery: Surgical Management of Pleural Diseases. St. Louis: Mosby, 1990: 336-343.
34. 34. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108; 1122-1128.
35. 35. Henderson DW, Comin CE, Hammar SP et al. Malignant mesothelioma of the pleura: current surgical pathology. In Corrin B ed. Pathology of Lung Tumors. New York: Churchill Livingstone, 1997: 241-280.
36. 36. Leong AS-Y, Milios J, Tang SK. Is immunolocalisation of proliferating cell nuclear antigen (PCNA) in paraffin sections a valid index of cell proliferation? Appl. Immunohistochem. 1993; 1; 127-135.